Shares of Orphazyme A/S (ORPH) soared as much as over 1,300%, touching an intraday price of $77.77, yesterday, as the company awaits FDA word on its lead drug candidate MIPLYFFA.MIPLYFFA, known generically as Arimoclomol, is proposed for the treatment of Niemann-Pick type C, a rare inherited lysosomal storage disorder, with the regulatory agency's decision expected on June 17, 2021.If approved, MI...
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.